MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 2, 2013 and December 3, 2013, the Company was informed by Dr. Eugene Bauer, a Director of the Company, that he sold a total of 20,000 shares of common stock on the open market on those days at an average price of $6.30 per share.
Help employers find you! Check out all the jobs and post your resume.
